Posted by Michael Wonder on 01 Jun 2023
Arcturus Therapeutics receives US FDA fast track designation for ARCT-810, mRNA therapeutic candidate for ornithine transcarbamylase deficiency
1 June 2023 - Arcturus Therapeutics today announced that the US FDA has granted fast track designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase deficiency.
ARCT-810 utilizes Arcturus’ mRNA design construct and proprietary manufacturing process.
